Effect of Gd-DTPA-BMA on choline signals of HT29 tumors detected by in vivo 1H MRS

Journal of Magnetic Resonance Imaging

Volumn 28, Issue 5, 2008, Pages 1201-1208

  Madhu, Basetti ^a   Robinson, Simon P ^b   Howe, Franklyn A ^c   Griffiths, John R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

1H MRS; Choline; Gd DTPA BMA; HT29 tumors

Indexed keywords

CHOLINE; GADODIAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HT29; COLON CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ALGORITHMS; CHOLINE; COLONIC NEOPLASMS; GADOLINIUM DTPA; HT29 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 55749092253     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21577     Document Type: Article

References (36)

1. 1H magnetic resonance spectroscopy. Neoplasia 2006;7:560-567.
2. McPhail LD, Chung YL, Madhu B, et al. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005;11:3705-3713.
3. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology 2005;236:465-475.
4. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-1203.
5. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715-721.
6. Fan G, Sun B, Wu Z, Guo Q, Guo Y. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004;59:77-85.
7. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neo-adjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001;84:1016-1022.
8. 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol 2002;75:959-966.
9. 1H MR spectroscopy - a pilot study at 4 T. Radiology 2004;233: 424-431.
10. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16:407-422.
11. Jacobs MA, Barker PB, Argani P, Ouwerkerk R, Bhujwalla ZM, Bluemke DA. Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging 2005;21:23-28.
12. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004;232:585-591.
13. 1H MR spectroscopy monitoring of changes in choline peak area and line shape after Gd-contrast administration. Magn Reson Imaging 1998;16:1273-1280.
14. 1H chemical shift imaging reveals loss of brain tumour choline signal after administration of Gd-contrast. Magn Reson Med 1997;37: 222-225.
15. 1-weighted choline signal in human brain tumours. Magn Reson Imaging 2002;20:127-130.
16. Lin AP, Ross BD. Short-echo time proton MR spectroscopy in the presence of gadolinium. J Comput Assist Tomogr 2001;25:705-712.
17. 1H MRS at 4T. RSNA Scientific Assembly. 2000; Abstract 278PH-P.
18. Joe BN, Chen VY, Salibi N, et al. Evaluation of 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. Invest Radiol 2005;40:405-411.
19. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007;23:131-154.
20. Provenzale JM, York G, Moya MG, et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. AJR Am J Roentgenol 2006;187:1036-1042.
21. Chen W, Giger ML, Bick U, Newstead GM. Automatic identification and classification of characteristic kinetic curves of breast lesions on DCE-MRI. Med Phys 2006;33:2878-2887.
22. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia, 2nd ed. Br J Cancer 1998;77:1-10.
23. 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1988;6:92-98.
24. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43.
25. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med 1990;14:26-30.
26. Saunders DE, Howe FA, van den Boogaart A, Griffiths JR, Brown MM. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J Magn Reson Imaging 1999;9:711-716.
27. Murphy PS, Leach MO, Rowland IJ. Signal modulation in (1)H magnetic resonance spectroscopy using contrast agents: proton relaxivities of choline, creatine, and N-acetylaspartate. Magn Reson Med 1999;42:1155-1158.
28. Xie D, Kennan RP, Gore JC. Measurements of the relaxivity of gadolinium chelates in tissue in vivo. In: Proc ISMRM, 2001; p 890.
29. Al-Saffar NM, Troy H, Ramirez de Molina A, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 2006;66:427-434.
30. Deichmann R, Adolf H, Kuchenbrod E, Noth U, Schwarzbauer C, Haase A. Compensation of diffusion effects in T2 measurements. Magn Reson Med 1995;33:113-115.
31. Hsu EW, Schoeniger JS, Bowtell R, Aiken NR, Horsman A, Blackband SJ. A modified imaging sequence for accurate T2 measurements using NMR microscopy. J Magn Reson B 1995;109:66-69.
32. De Stasio G, Casalbore P, Pallini R, et al. Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 2001;61:4272-4277.
33. De Stasio G, Rajesh D, Casalbore P, et al. Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? Neurol Res 2005;27:387-398.
34. De Stasio G, Rajesh D, Ford JM, et al. Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin Cancer Res 2006;12:206-213.
35. Nilsson S, Wikström M, Ericsson A, et al. MR imaging of double-contrast enhanced porcine myocardial infarction. Correlation with microdialysis. Acta Radiol 1995;36:346-352.
36. Terreno E, Botta M, Dastru W, Aime S. Gd-enhanced MR images of substrates other than water. Contrast Med Mol Imaging 2006;1: 101-105.